Phase 2 N=117 Traumatic Optic Neuropathy Treatment Trial (TONTT)
Traumatic Optic Neuropathy
Primary: Number of Participants With Change/Improvement Visual Acuity From the Beseline — 28; 3; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Usability of the CP950 Sound Processor
Hearing Loss
Primary: Patient Satisfaction Through Usability of the CP950 Sound Processor as Measured by the CP950 Take Home Questionnaire — 22; 28; 27; 28 Participants
N/A N=1,242 Service and Health During the Iraq and Afghanistan Era
Iraq and Afghanistan Era Veterans
Primary: Participation Rates — 137; 121; 14 Participants
Phase 2 N=475 Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
Escherichia Coli Diarrhea
Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants
Phase 2 N=25 Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Clear Cell Renal Cell Carcinoma · Stage I Renal Cell Cancer · Stage II Renal Cell Cancer
Primary: Number of Participants Who Could Undergo Partial Nephrectomy After Pazopanib Therapy — 6 Participants
Phase 2 N=18 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
Phase 2 N=78 Tivantinib in Treating Patients With Metastatic Prostate Cancer
Hormone-Resistant Prostate Cancer · Prostate Adenocarcinoma · Recurrent Prostate Carcinoma
Primary: Progression-free Survival (PFS) Based on the RECIST Criteria — 5.5; 3.7 months — p=0.02
N/A N=5 Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)
Treatment Resistant Depression · Depressive Disorder, Treatment-Resistant · Depression, Bipolar
Primary: Comparison of 12 Weeks of Left Unilateral DBS vs. 12 Weeks Right Unilateral DBS on Change in 17-item Hamilton Depression Rating Scale (HDRS-17) — 22.35; 18.8; 21.4; 17.4…
Phase 3 N=30 Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
Prostatic Neoplasms
Primary: Number of Participants With Adverse Events — 12; 1; 4 Participants
Phase 3 N=304 Long-term Open-Label Safety Study to Evaluate EN3409
Low Back Pain · Osteoarthritis · Neuropathic Pain
Primary: Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score — 0.2 units on a scale
Phase 2 N=5 Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events
N/A N=54 Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling
Cardiovascular Diseases
Primary: Effect of NO Inhibition on Myocardial Substrate Metabolism in Humans — NA; NA; NA; NA percentage of substrate
N/A N=180 Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation
Second Trimester Abortion
Primary: D&E Procedure Time — 7.35; 7.55 minutes
Phase 4 N=157 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation
Fluid Loss · Symptom Complex, Triple · Emergencies
Primary: Quality of Recovery-40 Score at 24 Hours — 166.8; 164.4 units on a scale — p=0.608
Phase 3 N=50 CPT and Smoking Cessation
Stress Disorders, Post-Traumatic · Smoking
Primary: Number of Participants Who Self-report 7-day Point Prevalence Smoking Abstinence at 6-month Follow-up. — 2; 8 Participants